Helen Y. Hougen

Helen Y. Hougen

Auto-generated profile, based on publicly available information

Helen Y. Hougen

Department of Urology, University of Iowa, Iowa City, IA 52242, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2022 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
STSze Kiat Tan
Sze Kiat Tan
HHHelen Y. Hougen
Helen Y. Hougen
JMJaime R. Merchan
Jaime R. Merchan
MGMark L. Gonzalgo
Mark L. Gonzalgo
SWScott M Welford
Scott M Welford

1 August 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
HHHelen Y. Hougen
Helen Y. Hougen
NSNishwant Swami
Nishwant Swami
EDEdward Christopher Dee
Edward Christopher Dee
MAMohammed Alshalalfa
Mohammed Alshalalfa
KMKarthik Meiyappan
Karthik Meiyappan
BMBrandon A. Mahal
Brandon A. Mahal
PURPOSE: Reporting racial/ethnic disparities in aggregate obscures within-group heterogeneity. We sought to identify disparities in diagnosis and treatment in Hispanic subpopulations with metastatic prostate cancer (mPCa). METHODS: We disaggregated men with prostate adenocarcinoma from the National Cancer Database from 2004 to 2017 by racial subgroup and Hispanic background. We assessed (1) presenting with mPCa, (2) receiving any treatment, and (3) receiving delayed treatment beyond 90 days. Logistic regression and adjusted odds ratios (aOR) were reported. RESULTS: Hispanic men had greater odds of presenting with mPCa (aOR, 1.54; 95% CI, 1.50 to 1.58; P < .001) compared with non-Hispanic White (NHW) men. All Hispanic racial subgroups were more likely to present with mPCa, with the highest risk in Hispanic Black (HB) men (aOR, 1.68; 95% CI, 1.46 to 1.93; P < .01). Men from all Hispanic backgrounds had higher odds of presenting with mPCa, especially Mexican men (aOR, 1.99; 95% CI, 1.86 to 2.12; P < .01). Hispanic men were less likely to receive any treatment (aOR, 0.60; 95% CI, 0.53 to 0.67; P < .001), and this effect was particularly strong for Hispanic White patients (aOR, 0.58; 95% CI, 0.52 to 0.66; P < .001) and Dominican men (aOR, 0.52; 95% CI, 0.28 to 0.98; P = .044). Hispanic men were more likely to experience treatment delays compared with NHW men (aOR, 1.38; 95% CI, 1.26 to 1.52; P < .001) and in particular HB (aOR, 1.83; 95% CI, 1.22 to 2.75; P = .002) and South/Central American men (aOR, 1.48; 95% CI, 1.07 to 2.04; P = .018). CONCLUSION: Differences exist in stage at presentation, treatment receipt, and delays in treatment on disaggregation by racial subgroup and Hispanic heritage. We need to study the potential mechanisms of the observed variations to help develop targeted interventions.

23 August 2023 in European Urology Open Science
Verified
Journal Article
Open access
HHHelen Y. Hougen
Helen Y. Hougen
RGRyon P. Graf
Ryon P. Graf
GLGerald Li
Gerald Li
JQJulia C.F. Quintanilha
Julia C.F. Quintanilha
DLDouglas I. Lin
Douglas I. Lin
BMBrandon A. Mahal
Brandon A. Mahal
Tumor mutational burden (TMB) is a biomarker that predicts response to immune checkpoint inhibitor therapy. We currently lack a comprehensive understanding of how genomic and clinical factors correlate with TMB. We used a clinicogenomic database to assess independent predictors of TMB levels. The study included 2740 prostate cancer specimens from prostate gland (51.6%), lymph nodes (14.6%), and bone (10.4%). Androgen deprivation therapy use beyond 24 mo was weakly associated with high TMB (fold-change estimate [FCE] 1.14, 95% confidence interval [CI] 1.03–1.26; p = 0.009). In comparison to the prostate gland, metastases in the bladder (FCE 1.20, 95% CI 1.02–1.42; p = 0.029), liver (FCE 1.26, 95% CI 1.10–1.43; p < 0.001), and other locations (FCE 1.26, 95% CI 1.11–1.43; p < 0.001) were associated with high TMB. Microsatellite instability high (FCE 8.46, 95% CI 6.42–11.15; p < 0.001) and intermediate (FCE 1.77, 95% CI 1.46–2.14; p < 0.001) status were associated with greater TMB. Altered genes associated with greater TMB included MLH1 (FCE 1.81; p = 0.004), MSH2 (FCE 1.87; p < 0.001), MSH6 (FCE 1.92; p < 0.001), BRCA2 (FCE 1.69; p < 0.001), CDK12 (FCE 1.40; p < 0.001), MRE11 (FCE 2.28; p = 0.016), and PALB2 (FCE 2.08; p < 0.001). Our study demonstrates that TMB is relatively stable over lines of therapies and can be used to guide treatment at diagnosis or in later lines for patients with metastatic prostate cancer. The number of genetic mutations in a tumor (tumor mutational burden, TMB) may help in predicting a patient’s response to immunotherapy in advanced prostate cancer. We evaluated clinical and genetic factors that may affect TMB. We found that metastases in the bladder and liver are more likely to have high TMB than the primary tumor. Some individual genes are associated with high TMB. No prior treatment type was strongly associated with TMB, suggesting that TMB can be used to guide treatment at any time point. These data were presented at the American Society of Clinical Oncology 2023 Genitourinary Cancers Symposium.

27 September 2024 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
HHHelen Y. Hougen
Helen Y. Hougen
IRIsildinha M. Reis
Isildinha M. Reis
SHSunwoo Han
Sunwoo Han
NPNachiketh Soodana Prakash
Nachiketh Soodana Prakash
JTJamie Thomas
Jamie Thomas
SPSanoj Punnen
Sanoj Punnen

27 October 2023 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
WJWill H. Jin
Will H. Jin
LZLiangliang Zhang
Liangliang Zhang
RGRyon Graf
Ryon Graf
KRKira Raskina
Kira Raskina
HTHanna Tukachinsky
Hanna Tukachinsky
BMBrandon A. Mahal
Brandon A. Mahal

17 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
IMIan Mitchell McElree
Ian Mitchell McElree
VPVignesh T Packiam
Vignesh T Packiam
RSRyan L. Steinberg
Ryan L. Steinberg
HHHelen Y. Hougen
Helen Y. Hougen
SMSarah L. Mott
Sarah L. Mott
MOMichael A. O’donnell
Michael A. O’donnell
Growing evidence suggests that many patients with high-risk non-muscle invasive urothelial carcinoma (NMIUC) can undergo bladder-sparing management with salvage intravesical therapies. However, inherent or developed disease resistance, particularly after multiple lines of prior salvage therapy, implores the continued pursuit of new treatment combinations. Herein, we describe the outcomes of 26 patients (31 treated units; 24 lower tract, 7 upper tract) with high-risk NMIUC treated with sequential intravesical gemcitabine and cabazitaxel with concomitant intravenous pembrolizumab (GCP) at the University of Iowa from August 2020 to February 2023. Median (IQR) follow-up was 30 (IQR: 17–35) months. Treated units had a history of high-risk NMIUC with a median of four prior endoluminal inductions. Overall, 87% of units presented with CIS or positive urine cytology. The 1- and 2-year recurrence-free survival was 77% (CI: 58–88%) and 52% (CI: 30–70%), respectively. The 2-year progression-free and cancer-specific survival was 70% (CI: 44–85%) and 96% (CI: 75–99%), respectively. In total, 22/26 (85%) patients reported any adverse event and 5/26 (19%) reported a grade ≥3 adverse event; however, all patients tolerated a full induction course. These results suggest that GCP is an effective and tolerable treatment option for patients with recurrent high-risk NMIUC.